Premium
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
Author(s) -
Morabito Fortunato,
Del Poeta Giovanni,
Mauro Francesca Romana,
Reda Gianluigi,
Sportoletti Paolo,
Laurenti Luca,
Coscia Marta,
Herishanu Yair,
Bossio Sabrina,
Varettoni Marzia,
Murru Roberta,
Chiarenza Annalisa,
Visentin Andrea,
Condoluci Adalgisa,
Moia Riccardo,
Pietrasanta Daniela,
Loseto Giacomo,
Consoli Ugo,
Scortechini Ilaria,
Recchia Anna Grazia,
Rossi Francesca Maria,
Zucchetto Antonella,
AlJanazreh Hamdi,
Martino Enrica Antonia,
Vigna Ernesto,
Tripepi Giovanni,
D'Arrigo Graziella,
Galimberti Sara,
Rago Angela,
Angeletti Ilaria,
Biagi Annalisa,
Del Giudice Ilaria,
Bomben Riccardo,
Neri Antonino,
Fronza Gilberto,
Cutrona Giovanna,
Jaksic Ozren,
Olivieri Jacopo,
Rossi Davide,
Di Raimondo Francesco,
Cuneo Antonio,
Gaidano Gianluca,
Polliack Aaron,
Trentin Livio,
Foà Robin,
Ferrarini Manlio,
Gattei Valter,
Gentile Massimo
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26235
Subject(s) - medicine , chronic lymphocytic leukemia , multicenter study , retrospective cohort study , oncology , risk factor , leukemia , immunology , randomized controlled trial